Revision History

New guidelines from the American Heart Association and American College of Cardiology now recommend that all adults receive a one-time test for lipoprotein(a), a genetically determined cholesterol particle that can double or triple heart attack risk and has been largely ignored in routine screenings. The sweeping 2026 dyslipidemia guidelines also lower the age for considering statin therapy from 40 to 30 and introduce a more accurate risk calculator, representing the most significant overhaul of cardiovascular prevention strategy in nearly a decade.